Month: November 2022

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The first dynamic NFT game project will leverage dNFT technology to make strides in the worlds of blockchain and gaming.

Featured Image for Intergalactic Social Media, LLC

Featured Image for Intergalactic Social Media, LLC

RICHMOND, Va., Nov. 24, 2022 (GLOBE NEWSWIRE) — Intergalactic Social Media, a collective of crypto advisors and developers spearheaded by founders John Nguyen and Phea Ram, has officially launched its first NFT project, the Galactix Zone. The project, which has now been in development for over two years, is a community-focused effort utilizing a unique Non-Fungible Token (NFT) known as a Dynamic Non-Fungible Token (dNFT). Through its innovative design and model, Intergalactic Social Media aims to break through the mold by redefining NFTs and gaming itself.

After observing several NFT projects, Nguyen and Ram concluded that there was substantial potential for future opportunities and innovations within the space. Over time, they grew increasingly aware of the concerns surrounding the NFT space, including projects that seemed to promote static pixels in an attempt to merely ride a “hype train” and generate quick capital. Other projects went one step further and promised assets to investors just to completely fail to deliver on any of their previous promises.

Galactix Zone, also known as Galactix Zone Kalpa Avian or GKA, will set itself apart through innovations made possible by dNFT technology. Through dNFT, unique properties can be added or removed through the minting process. This innovation is merely scratching the surface of what is to come; GKA is scheduled to be just the first of several projects planning to be released in the ecosystem.

Unlike other projects that promote static NFT images, the Galactix Zone will feature dNFT assets that exist as living, breathing entities with synergistic integration and utility. This unique model gives our project the flexibility to truly innovate in the NFT space.

The implementation of the Galactix Zone project is currently pending internal review, with a detailed release soon to come. The Certik Audit and Certik KYC began on Oct. 31. The Galactix Zone team received a KYC Silver Verified rating on 11/21/2022 and a GEO RISK of a Tier 1 rating – The core team is in a country with the best ratings for international judicial cooperation, criminal justice, anti-money laundering, and corruption. Contextual data suggests the maximum level of geographical accountability, maximizing risk reduction and mitigation. A Certik (Certik.com) audit is an industry-leading security audit for web3 projects. This type of audit assesses smart contracts and blockchain code to address security concerns and identify vulnerabilities. A CertiK Know Your Customer (KYC) verification check is designed to put project teams through a rigorous vetting process while maintaining the highest standards of data protection.

Through these audits and verification checks, the Intergalactic Social Media team hopes to instill a strong sense of trust and transparency within the greater Galactix Zone community.

“Trust and transparency are fundamental principles for our project,” said Nguyen, who serves as the company’s CEO. “These processes will help ensure our community of who we are, what intentions we have currently, and what our future goals for the project will be. Ensuring trust and security is our top priority.”

The Intergalactic Social Media team plans to set aside one percent of its total token supply to be given to charity when the price hits $0.79. The time it will take for the token to reach that price will be determined by the level of pure synergetic teamwork between the developers and the community working together.

“We like to say that ‘FITS’ is in our DNA. FITS stands for fun, innovation, technology, and sustainability,” said Phea, who serves as CTO of Intergalactic Social Media.

“John and I were so captivated by the idea of decentralization when we first began reading about it. It can be so beneficial to all and used as a force for good. With that being said, we gave many of the early projects the benefit of the doubt, only to be burned by bad actors within the industry. We are determined to be different. Giving back to our community is a major focus of ours. We go as far as to say that it is in our tokenomics DNA.”

To learn more about the Galactix Zone, check out the team’s official project announcement video.

About Intergalactic Social Media, LLC

Intergalactic Social Media, LLC is the developer of the Galactix Zone project. Now in development for over two years, the project was initially founded by crypto investors John Nguyen, who serves as the CEO of Intergalactic Social Media, and Phea Ram, who serves as CTO.

In conjunction with a large team of advisors and developers, Nguyen and Ram have worked to bring Galactix Zone, the community-based game focused on giving back to society, to life.

https://discord.gg/2UqSqFJtbA

https://github.com/GalactixZone

https://www.tiktok.com/@galactixzone.io

https://twitter.com/GalactixZone

https://www.youtube.com/@galactixzone

https://www.instagram.com/galactixzone.io

https://www.facebook.com/galactixzone.io

https://www.linkedin.com/company/galactix-zone

Contact Information:
Phea Ram
CTO
marketing@galactixzone.io

Related Files

Galactix Zone Tokenomics 11-23-22.pdf

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Featured Image for Intergalactic Social Media, LLC

GlobeNewswire Distribution ID 8702894

— 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization

SHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for toripalimab. The indications requested in the MAA are: 1) Toripalimab, in combination with cisplatin and gemcitabine, for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and 2)Toripalimab, in combination with paclitaxel and cisplatin, for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”). Junshi Biosciences also submitted a MAA to the European Medicines Agency (“EMA”) for toripalimab for the same indications in mid-November.

“Within a single month, we were able to submit marketing authorization applications for toripalimab to two major European regulatory agencies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi/TopAlliance Biosciences. “This is emblematic of our determination and corporate efficiency in bringing innovative drugs to patients worldwide. In the coming days, we will work closely with the MHRA to promote the clinical development and application of emerging therapies in the UK.”

The MAA submission for NPC and ESCC is based on the results from JUPITER-02 (an international randomized, placebo-controlled, double-blinded Phase III trial, NCT03581786) and JUPITER-06 (a randomized, placebo-controlled, double-blinded, multi-center Phase III trial, NCT03829969).

The JUPITER-02 results were first presented in the plenary session of the American Society of Clinical Oncology (“ASCO”) 2021 annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. According to its final progression-free survival (PFS) analysis, the toripalimab plus chemotherapy arm had a significantly longer PFS than the placebo plus chemotherapy arm as assessed by a blinded independent radiology committee (BIRC) with median PFS of 21.4 vs. 8.2 months, hazard ratio (HR)=0.52 (95% CI: 0.37-0.73), two-sided p<0.0001.

In 2021, two indications for the treatment of NPC were approved by the China National Medical Products Administration (“NMPA”), thereby making toripalimab the world’s first immune checkpoint inhibitor approved for the treatment of NPC. In the the United States, the NPC indications of toripalimab have been granted 2 Breathrough Therapy Designations and 1 Orphan Drug Designation by the Food and Drug Administration (“FDA”), while the Biologics License Application (“BLA”) for toripalimab for the treatment of NPC is under review. If approved, toripalimab will be the first and only drug approved for the treatment of NPC in the U.S. In Europe, toripalimab was designated as an orphan medicinal product by the European Commission (“EC”) for the treatment of NPC.

The JUPITER-06 results were first presented in a mini-oral session during the 2021 European Society for Medical Oncology (“ESMO”) Congress and later published in Cancer Cell with an editorial preview. The overall survival (OS) and PFS were significantly better in the toripalimab plus chemotherapy arm than in the placebo plus chemotherapy arm, with a median OS of 17 vs. 11 months (HR=0.58, 95% CI: 0.43-0.78, P=0.0004) and PFS HR=0.58 (95% CI: 0.46-0.74), p<0.0001.

In May 2022, the supplemental new drug application (“sNDA”) for toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC was approved by the NMPA in China. Additionally, US FDA has also granted an orphan drug designation to toripalimab for the treatment of patients with ESCC.

About Nasopharyngeal Carcinoma
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers in China. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no drugs approved for the treatment of NPC, for which recommendations for initial treatment (gemcitabine and cisplatin) are based on randomized trials conducted in China.

About Esophageal Cancer
Esophageal cancer is one of the most common malignant tumors in alimentary tract. According to data released by GLOBOCAN 2020, 604,100 new esophageal cancer cases and 544,076 deaths due to esophageal cancer occurred globally. The incidence and death rates of esophageal cancer ranked seventh and sixth among all malignant tumors around the world. ESCC and esophageal adenocarcinoma are the two main histological subtypes of esophageal cancer. For patients with advanced ESCC, recently updated ESMO guidelines recommend a platinum-fluoropyrimidine doublet with a PD-1 blocking antibody for treatment of locally advanced or metastatic ESCC. Of note, the indications for those PD-1 inhibitors approved in Europe are restricted to a subset of patients with ESCC. Therefore, there is an urgent unmet need for new drugs and treatments to extend the survival of patients with ESCC, particularly those with low PD-1 tumor expression.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI^®). Currently, there are six approved indications for toripalimab in China:

1. unresectable or metastatic melanoma after failure of standard systemic therapy;
2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC;
6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (“NRDL”) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma and NPC.

In the United States, the FDA is reviewing the BLA resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a PDUFA action date for December 23, 2022. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (“SCLC”).

In Europe, toripalimab was also designated as an orphan medicinal product by the EU’s European Commission for the treatment of NPC. In November 2022, MAA was submitted to the EMA and MHRA for: 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8703015

Amsterdam, 24 November 2022 – Today, Azerion has announced the acquisition of AdPlay, an Italian based digital advertising platform. Together, the companies will provide advertisers with access to even larger audiences in Italy through exciting new formats and content like digital out of home and first look at highly relevant sports content. At the same time, publishing partners will benefit from the additional revenues and advertising formats Azerion will bring to them.

Umut Akpinar, co-CEO of Azerion, comments: “I am pleased to announce the acquisition of AdPlay and strengthen our advertising business in Italy. The AdPlay team is a perfect fit with our Azerion culture, and their local expertise and experience will add to our ability to help our Italian customers to get the results they need from their advertising budgets. I am also very excited to welcome AdPlay’s Italian partners to the Azerion platform and grow our business together with them as well as extending our connected TV and digital out of home reach in the local market.”

Azerion will integrate AdPlay’s digital cross-media solutions and campaign performance management, adding to its robust current offering in these areas. AdPlay exclusively represents some of the most relevant Italian publishers and has been pioneering the digital out of home market in Italy. Through this acquisition, Azerion will strengthen its position in Italy and increase its relevance as a partner that delivers easy, impactful and affordable access to large and diverse audiences through highly engaging content.

Additionally, AdPlay recently launched Veedly, a dedicated solution focused on the distribution of on-demand multimedia content from the world of sports. Veedly is already cooperating with various sports leagues.

The aggregated consideration is a combination of cash and shares. In total, 580,470 treasury shares were transferred to the selling shareholder. The  transaction is effective as of 11th November 2022. AdPlay generated approximately €12 million gross revenue in 2021.

This announcement follows various previous acquisitions in 2022, as Azerion continues to execute on its growth strategy. So far this year, Azerion has acquired an estimated annualised revenue in the range of €100 million to €125 million for a total aggregated consideration (combination of cash and shares) in the range of €90 million to €100 million.

About Azerion

Azerion is a high-growth digital entertainment and media platform. As a content-driven, technology and data company, Azerion serves consumers, digital publishers, advertisers, and game creators globally. Azerion’s integrated platform provides technology solutions to automate the purchase and sale of digital advertising for media buyers and sellers, supported by in-market sales and campaign management teams. Through our technology, content creators, digital publishers and advertisers work with Azerion to reach the millions of people across the globe that play Azerion’s games and view its distributed entertainment content to increase engagement, loyalty, and drive e-commerce.

Founded in 2014 by two Dutch entrepreneurs, Azerion has experienced rapid expansion driven by organic growth and strategic acquisitions. Azerion is headquartered in Amsterdam, the Netherlands and is a publicly traded company listed on Euronext Amsterdam. For more information visit: www.azerion.com.

About AdPlay

AdPlay is a tech media company focused on the development of proprietary solutions for Publishers and Brand advertisers. AdPlay Media Holding is a strategic partner for the implementation of digital transformation and innovation plans, through its owned technologies and tailored consulting services.

Contact
Investor Relations
ir@azerion.com

Media
press@azerion.com

GlobeNewswire Distribution ID 1000768652

COPENHAGEN, Denmark, Nov. 24, 2022 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners (CIP) through its CI Advanced Bioenergy Fund I (CI ABF I) has secured two sites (La Sentiu and Linyola) for two large industrial scale biogas plants located in Catalonia, Spain. The La Sentiu project has been appointed a project of strategic importance by the Catalan government which implies that the permit application for the plant will be prioritized by the Catalan government and administration.

CIP will together with Spanish developer, Connect Bioenergy, develop the biogas plants towards expected Final Investment Decision in 2024.

The biogas plants will use green sustainable feedstock (organic waste): Pig manure from local farms, slaughterhouse waste and other industrial organic waste. The plants will produce green gas (biomethane) to be injected into the existing natural gas grid and contribute to circularity, as the organic materials will be recirculated as nutrients (fertilizer) for agricultural production and produce biogen CO₂ for industrial use or for Power-to-X projects. The two biogas plants are expected to deliver a total CO2 emissions savings of more than 150,000 tons annually.

The plants will deliver on both the long-term need for energy security and independence and deliver on the decarbonization of hard to abate sectors. Additionally, they will aid local job creation and will be part of the solution to the regional challenge with a surplus of nutrients in the soil and waterways caused by the concentration of agricultural production.

“We continue to see great potential in an efficient conversion of organic waste to green gas and green fuels. We believe that advanced bioenergy plays a key role in the green transition with replacement of fossil natural gas. The status of strategic importance for the La Sentiu project is an important milestone and a testimony of recognition of local support from the Catalan government. We look forward to continuing the good collaboration with our partners and local stakeholders, and to finalise the development of the project which will contribute significantly to the reduction of greenhouse gas emissions and create new local jobs,” says Thomas Dalsgaard, Partner at CIP.

The Danish biogas technology provider, Lundsby Biogas A/S, will as minority shareholder take part in the development of the project.

CI ABF I is investing in advanced bioenergy plants in Europe and North America. It enables institutional investors to contribute to the energy transition and participate in the decarbonization of hard to abate sectors through the production of advanced biofuels and biogas. The fund reached second close of ~EUR 500 million in September 2022 and has a target fund size of EUR 1 billion. In addition to the biogas plants in Spain, CI ABF I is currently building a pipeline of advanced bioenergy projects across its target markets in Europe and North America. CI ABF I is classified as an Article 9 “dark green” fund under the EU Sustainable Finance Disclosure Regulation (SFDR).

About Copenhagen Infrastructure Partners
Founded in 2012, CIP today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore- and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity and storage, Power-to-X and advanced bioenergy.

CIP manages ten funds and has to date raised approximately EUR 19 billion for investments in energy and associated infrastructure from more than 140 international institutional investors. CIP will accelerate its role in the global energy transition and aims to have EUR 100 billion under management in green energy investments by 2030. CIP has approximately 370 employees and offices in Copenhagen, London, Hamburg, Utrecht, New York, Tokyo, Singapore, Seoul, and Melbourne. For more information, visit www.cip.dk

About Connect Bioenergy
Connect Bioenergy is a project development company in the field of RNG (renewable natural gas). Connect Bioenergy has a mix of strong local presence in the farmer and local community in the Lleida region of Catalonia together with knowledge of the Spanish energy market.

About Lundsby
Lundsby has more than 25 years of experience in the development and delivery of individually designed biogas plants in various sizes and for multiple applications. Lundsby specialize in building high-performance biogas plants with focus on building robust, flexible and reliable plants.

For further information, please contact:

Copenhagen Infrastructure Partners
Simon Mehl Augustesen, Chief Communication & Marketing Officer
Phone: +45 30526721
Email: siau@cip.dk

Thomas Kønig, Partner – Investor Relations
Phone: +45 7070 5151
Email: tkon@cip.dk

GlobeNewswire Distribution ID 1000768510

Amsterdam, 24 November 2022 – Today, Azerion has announced the acquisition of AdPlay, an Italian based digital advertising platform. Together, the companies will provide advertisers with access to even larger audiences in Italy through exciting new formats and content like digital out of home and first look at highly relevant sports content. At the same time, publishing partners will benefit from the additional revenues and advertising formats Azerion will bring to them.

Umut Akpinar, co-CEO of Azerion, comments: “I am pleased to announce the acquisition of AdPlay and strengthen our advertising business in Italy. The AdPlay team is a perfect fit with our Azerion culture, and their local expertise and experience will add to our ability to help our Italian customers to get the results they need from their advertising budgets. I am also very excited to welcome AdPlay’s Italian partners to the Azerion platform and grow our business together with them as well as extending our connected TV and digital out of home reach in the local market.”

Azerion will integrate AdPlay’s digital cross-media solutions and campaign performance management, adding to its robust current offering in these areas. AdPlay exclusively represents some of the most relevant Italian publishers and has been pioneering the digital out of home market in Italy. Through this acquisition, Azerion will strengthen its position in Italy and increase its relevance as a partner that delivers easy, impactful and affordable access to large and diverse audiences through highly engaging content.

Additionally, AdPlay recently launched Veedly, a dedicated solution focused on the distribution of on-demand multimedia content from the world of sports. Veedly is currently collaborating with the official digital channels of Lega Serie A, allowing for content distribution of various kinds, including highlights of all the Serie A TIM matches, and Coppa Italia Frecciarossa for the next two sports seasons.

The aggregated consideration is a combination of cash and shares. In total, 580,470 treasury shares were transferred to the selling shareholder. The  transaction is effective as of 11th November 2022. AdPlay generated approximately €12 million gross revenue in 2021.

This announcement follows various previous acquisitions in 2022, as Azerion continues to execute on its growth strategy. So far this year, Azerion has acquired an estimated annualised revenue in the range of €100 million to €125 million for a total aggregated consideration (combination of cash and shares) in the range of €90 million to €100 million.

About Azerion

Azerion is a high-growth digital entertainment and media platform. As a content-driven, technology and data company, Azerion serves consumers, digital publishers, advertisers, and game creators globally. Azerion’s integrated platform provides technology solutions to automate the purchase and sale of digital advertising for media buyers and sellers, supported by in-market sales and campaign management teams. Through our technology, content creators, digital publishers and advertisers work with Azerion to reach the millions of people across the globe that play Azerion’s games and view its distributed entertainment content to increase engagement, loyalty, and drive e-commerce.

Founded in 2014 by two Dutch entrepreneurs, Azerion has experienced rapid expansion driven by organic growth and strategic acquisitions. Azerion is headquartered in Amsterdam, the Netherlands and is a publicly traded company listed on Euronext Amsterdam. For more information visit: www.azerion.com.

About AdPlay

AdPlay is a tech media company focused on the development of proprietary solutions for Publishers and Brand advertisers. AdPlay Media Holding is a strategic partner for the implementation of digital transformation and innovation plans, through its owned technologies and tailored consulting services.

Contact
Investor Relations
ir@azerion.com

Media
press@azerion.com

GlobeNewswire Distribution ID 1000768580

TUSK PRODUCT

TUSK PRODUCT ZEN

LONDON, Nov. 24, 2022 (GLOBE NEWSWIRE) — Tusk Inc. Limited (www.tusklimited.com) a company which started in 2012 as a capital management company in the United Kingdom and Kuala Lumpur with offices around the world, and now is one of the leading electrical solution companies which focus on producing for users of mining equipment, solar energy and adapters is announcing is k new products combo. The Product line is mainly for electrical purposes. For any miner bought, it comes with a solar panel, to reduce power consumption. See products here https://tusklimited.com/products

As one of the top Electrical solution companies, Tusk innovation has announced 30% discounts on its combo of mining equipment, which combines a solar panel with a bitcoin miner. With their recent movement from polycrystalline to photovoltaic materials, Tusk inc. has tested over time the efficiency of combining their solar products with cryptocurrency miners, and this has proven to be the most effective. Tusk inc. investors can now with ease, mine their coins without interruptions, lesser risks and maximum profit.

This is an effort to reduce the amount of electricity used when clients mine cryptocurrencies, and it was disclosed by the COO, John Walls, last week. According to Walls, “Reports going around made it evident that the quantity of electricity miners require may be too large to handle, therefore we obtained a plausible option.”

Mining Profits
Although it is admirable and highly profitable for many people to set up cryptocurrency mining farms, speculations are rife that they may incur significant costs, particularly in terms of electricity use. By providing you with a Solar Panel, which is unconnected to your electricity bills and a bitcoin mining device that can perform dual mining tasks, Tusk Inc. has created a long-lasting solution. You can simply mine your coins and not bother about the market’s volatility, while also ignoring power consumption.

Tusk Inc. has distinguished itself from others, in that customers can get crypto wallet development services as well as graphics processing units from the company, which has offices on three continents. It also has extensive experience in Blockchain development and bitcoin mining solutions, among other areas.

About Tusk
Established in 2012 by team of management experts, and later joined by a team of technology experts, Tusk Inc. is now one of the leading electrical solution providers. They pride themselves also in their ability to manage risk effectively, since they have been in the business of managing risks for over a decade. And through several advancements in technology, they have incorporated less risky ventures into the Risk Management system, one of which is cryptocurrency mining, using photovoltaic materials.

John Walls
PR Manager
john@tusklimited.com
(+44)7451214344

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/94500cd7-ba35-4ad9-8179-1f5f89263358

GlobeNewswire Distribution ID 1000768596

New York, U.S.A., Nov. 23, 2022 (GLOBE NEWSWIRE) — The UN Global Compact today released new guidance for business on how they can adapt to minimize climate change risks and impacts on their operations and supply chains in a just and equitable manner.

Just Transition for Climate Adaptation, developed by the Stockholm Environment Institute with inputs from partners and company participants in the Think Lab on Just Transition, introduces Just Transition and how it links to climate adaptation, and makes recommendations for businesses to achieve a fair and inclusive journey to a net-zero and resilient future.

According to the International Labour Organization, a just transition means greening the economy in a way that is as fair and inclusive as possible to everyone concerned, creating decent work opportunities and leaving no one behind. Climate impacts and risks can have knock-on effects along supply chains, affecting businesses, workers, livelihoods and communities. Companies need to engage in adaptation action that avoids redistributing risk or leaving workers, their communities and downstream suppliers behind.

The brief outlines seven recommendations for business to achieve a just transition for climate adaptation:

• Integrate social and environmental objectives into the business strategy through a social dialogue;
• Build coalitions, including with competitors;
• Improve data collection and sharing;
• Strengthen supply-chain resilience;
• Finance a just transition and climate adaptation;
• Partner with local and regional governments to devise adaptation strategies that advance a just transition;
• Advocate for clear division of responsibilities for a just transition, also to support climate adaptation.

Sanda Ojiambo, Assistant Secretary-General and CEO of the UN Global Compact commenting on the release of the guidance said:

“Businesses around the world are already experiencing the impacts of climate change from disrupted production, broken supply chains to increased costs. Implementing climate adaptation strategies can create new jobs, new innovations and new opportunities for business but only if it is done in a way that is inclusive and enables everyone to thrive. ”

Richard Klein, IPCC Lead Author and Team Leader, International Climate Risk and Adaptation at the Stockholm Environment Institute, and co-author of the guidance, said:  “Climate change risks and impacts expose vulnerabilities for most businesses today. A just transition for climate adaptation can help businesses integrate environmental and social work into their core business strategy and ensure long-term resilience for companies, their workers as well as local communities.”

For details and additional insights, please read the Brief.

Notes to Editors 

About the Think Lab on Just Transition

The Think Lab on Just Transition aims to shape and define business and thought leadership on critical areas linked to just transition; address key business challenges; identify policy advocacy opportunities and good business practices; and scale-up learnings through the UN Global Compact’s network. 27 company participants from across the globe include A.P. Møller – Mærsk, Accenture, AIA Group, CEMEX, DP World, Enara Capital, Enel SpA, Garanti BBVA, Iberdrola, Johnson Controls, Lenovo Group, LONGi, Mahindra Group, Majid Al Futtaim, Meta, Microsoft, Moody’s Corporation, National Australia Bank, Nestlé, Novozymes A/S, Ørsted, ReNew Power Pvt. Ltd., Sappi Southern Africa Ltd., TriCiclos, Unilever, Wipro Ltd. and Woolworths Holdings Limited. The partners of the Think Lab include UN Climate Change (UNFCCC), UN Environment Programme (UNEP), International Labour Organization, International Trade Union Confederation (ITUC) and its Just Transition Center, CDP, Duke University, Institute for Human Rights & Business (IHRB), International Organization of Employers (IOE), International Renewable Energy Agency (IRENA), Principles for Responsible Investment (PRI), Stockholm Environment Institute (SEI), Sustainable Energy for All (SEforALL), The B Team, UNICEF and World Resources Institute (WRI). Think Lab activities leverage synergies with the UN Global Compact’s “CFO Coalition for the SDGs” and the “Just Transition Maritime Task Force”.

About the United Nations Global Compact

As a special initiative of the UN Secretary-General, the United Nations Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 15,000 companies and 3,000 non-business signatories based in over 160 countries, and 69 Local Networks, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world.

For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org

Contact

Alex Gee
UN Global Compact
gee@unglobalcompact.org 
media@unglobalcompact.org

United Nations Global Compact
(212) 907-1301
media@unglobalcompact.org

GlobeNewswire Distribution ID 8702885